Healthcare companies with rare disease focus are relying on outsourcing like any other company involved in the product development and commercialization of new medicines.
Whereas today biopharmaceutical companies operating in the common disease field can refer to a broad base of full-service providers, it becomes difficult to select appropriate providers that can address the particular challenges that rare diseases entail. There is also no service solution available that addresses all aspects and offers a holistic approach to the particularities of dealing with orphan drugs keeping the patient in mind at the centre of all activities.
Orphan Reach are in business to provide the biopharmaceutical industry with the ultimate product lifecycle solution including clinical support and integrated patient management.
The purpose of Orphan Reach is to expedite the development of orphan drugs and facilitate patient access to treatments which can improve the quality of life of patients and their families. By driving best practice our team can provide continued, seamless, high quality support to biopharmaceutical companies throughout any stage of the orphan product lifecycle, a service that has not previously been available.
The Orphan Reach advantage
